Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sounding The Alarm On The Future Of CNS Drug Development

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The drug development paradigm for new central nervous system therapeutics is in need of a thorough reimagining, Tufts Center for the Study of Drug Development researchers assert in an analysis published in Scientific American.

You may also be interested in...



CNS Products Primed For “Breakthrough” Benefits

Tufts study indicates early talks with FDA could particularly help central nervous system product sponsors and their long clinical development programs.

APA Takeaways: Former Sanofi Exec Reflects On DSM-5, Eroom’s Law And More

The recent American Psychiatric Association annual meeting featured a lecture on drug development by Sanofi’s former head of CNS development Robert Lenox. In a post-meeting interview, he weighs in on the highs and lows of psychiatric drug development, as well as the newly released fifth edition of the Diagnostic and Statistical Manual of Mental Disorders.

Specialty Pharma Dominates Epilepsy Market, But Does It Have Resources To Develop Disease-Modifying Agents?

Upsher-Smith’s recent acquisition of research boutique Proximagen highlights the dynamics of the market: specialty pharma extending dominance and introducing new agents to the market, while most early R&D activity originates at small firms. But it may be difficult for this combination of players to bring forth the game-changing therapies that are needed, given the technical challenges of the disease space.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS004818

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel